[123I]FP-CIT SPECT Shows a Pronounced Decline of Striatal Dopamine Transporter Labelling in Early and Advanced Parkinson's Disease

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1997 Feb 1

PMID 9048712

Citations 105

Authors

J Booij

G Tissingh

G J Boer

J D Speelman

J C Stoof

A G Janssen

E C Wolters

E A van Royen

Affiliations

Soon will be listed here.

Abstract

Objectives: The main neuropathological feature in Parkinson's disease is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine (DA) transporters in the striatum. [123I]beta-CIT single photon emission computed tomography (SPECT) studies have demonstrated this loss of striatal DA transporter content in Parkinson's disease in vivo. However, studies with this radioligand also showed that an adequate imaging of the striatal DA transporter content could only be performed on the day after the injection of radioligand, which is not convenient for outpatient evaluations. Recently, a new radioligand [123I]FP-CIT, with faster kinetics than beta-CIT, became available for imaging of the DA transporter with SPECT, and the applicability of this ligand was tested in patients with early and advanced Parkinson's disease, using a one day protocol.

Methods: [123I]FP-CIT SPECT was performed in six patients with early and 12 patients with advanced Parkinson's disease, and in six age matched healthy volunteers.

Results: Compared with an age matched control group striatal [123I]FP-CIT uptake in patients with Parkinson's disease was decreased, and this result was measurable three hours after injection of the radioligand. In the Parkinson's disease group the uptake in the putamen was reduced more than in the caudate nucleus. The contralateral striatal uptake of [123I]FP-CIT was significantly lower than the ipsilateral striatal uptake in the Parkinson's disease group. Specific to non-specific striatal uptake ratios correlated with the Hoehn and Yahr stage. A subgroup of patients with early Parkinson's disease also showed significantly lower uptake in the putamen and lower putamen:caudate ratios than controls.

Conclusion: [123I]FP-CIT SPECT allows a significant discrimination between patients with Parkinson's disease and age matched controls with a one day protocol, which will be to great advantage in outpatient evaluations.

Citing Articles

Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders.

Scheifele M, Gnorich J, Schroder E, Kunte S, Ells Z, Hagen J Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40064709 DOI: 10.1007/s00259-025-07188-0.

Utility of Combining Transcranial Sonography and MIBG Myocardial Scintigraphy to Evaluate Substantia Nigra in Patients with Parkinson's Disease.

Mizukami H, Shiraishi M, Hino S, Kaburagi M, Matsumoto H, Hagiwara Y Brain Sci. 2024; 14(6).

PMID: 38928525 PMC: 11201763. DOI: 10.3390/brainsci14060524.

Long-Term Impact of Diffuse Traumatic Brain Injury on Neuroinflammation and Catecholaminergic Signaling: Potential Relevance for Parkinson's Disease Risk.

Wee I, Arulsamy A, Corrigan F, Collins-Praino L Molecules. 2024; 29(7).

PMID: 38611750 PMC: 11013319. DOI: 10.3390/molecules29071470.

Verification of optimal conditions for the scattering correction of I-FP-CIT SPECT on a single-photon emission tomography system with a two-detector whole-body cadmium-zinc-telluride semiconductor detector.

Izawa D, Ito T, Sanada H, Oku T, Nakamoto A, Hiraki H Radiol Phys Technol. 2023; 16(4):569-577.

PMID: 37804463 DOI: 10.1007/s12194-023-00746-x.

Generative adversarial network-based attenuation correction for Tc-TRODAT-1 brain SPECT.

Du Y, Jiang H, Lin C, Peng Z, Sun J, Chiu P Front Med (Lausanne). 2023; 10:1171118.

PMID: 37654658 PMC: 10465694. DOI: 10.3389/fmed.2023.1171118.

References

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, SEITELBERGER F . Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973; 20(4):415-55. DOI: 10.1016/0022-510x(73)90175-5. View

Hornykiewicz O, Kish S . Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 1987; 45:19-34. View

Kish S, Shannak K, Hornykiewicz O . Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318(14):876-80. DOI: 10.1056/NEJM198804073181402. View

Tedroff J, Aquilonius S, Hartvig P, Lundqvist H, Gee A, Uhlin J . Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand. 1988; 77(3):192-201. DOI: 10.1111/j.1600-0404.1988.tb05894.x. View

Gibb W, Lees A . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6):745-52. PMC: 1033142. DOI: 10.1136/jnnp.51.6.745. View

De Keyser J, De Backer J, Ebinger G, Vauquelin G . [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989; 53(5):1400-4. DOI: 10.1111/j.1471-4159.1989.tb08530.x. View

Goto S, Hirano A, Matsumoto S . Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol. 1989; 26(6):766-70. DOI: 10.1002/ana.410260613. View

Allard P, Marcusson J . Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen. Neurobiol Aging. 1989; 10(6):661-4. DOI: 10.1016/0197-4580(89)90001-8. View

10.

Zigmond M, Abercrombie E, Berger T, Grace A, Stricker E . Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990; 13(7):290-6. DOI: 10.1016/0166-2236(90)90112-n. View

11.

Farde L, von Bahr C . Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl. 1990; 358:67-71. DOI: 10.1111/j.1600-0447.1990.tb05292.x. View

12.

Brooks D, Ibanez V, Sawle G, Quinn N, Lees A, Mathias C . Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990; 28(4):547-55. DOI: 10.1002/ana.410280412. View

13.

Leenders K, Salmon E, Tyrrell P, Perani D, Brooks D, Sager H . The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990; 47(12):1290-8. DOI: 10.1001/archneur.1990.00530120034007. View

14.

Kaufman M, Madras B . Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991; 9(1):43-9. DOI: 10.1002/syn.890090107. View

15.

Langston J, Widner H, Goetz C, Brooks D, Fahn S, Freeman T . Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992; 7(1):2-13. DOI: 10.1002/mds.870070103. View

16.

Kilbourn M, Sherman P, Pisani T . Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol. 1992; 216(1):109-12. DOI: 10.1016/0014-2999(92)90216-q. View

17.

Brooks D . Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 1993; 115(1):1-17. DOI: 10.1016/0022-510x(93)90061-3. View

18.

Laruelle M, Baldwin R, Malison R, Zea-Ponce Y, Zoghbi S, Sybirska E . SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993; 13(4):295-309. DOI: 10.1002/syn.890130402. View

19.

Frost J, Rosier A, Reich S, Smith J, Ehlers M, Snyder S . Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993; 34(3):423-31. DOI: 10.1002/ana.410340331. View

20.

Innis R, Seibyl J, Scanley B, Laruelle M, Abi-Dargham A, Wallace E . Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993; 90(24):11965-9. PMC: 48106. DOI: 10.1073/pnas.90.24.11965. View